Corvus Pharmaceuticals suffered lately, especially after it announced in December 2024 its early AD data. Check out why I ...

Corvus Pharmaceuticals reported positive Phase 1/1b trial data for soquelitinib in T cell lymphoma, showing significant anti-tumor activity. Corvus Pharmaceuticals, Inc. announced new findings ...

Corvus Pharmaceuticals has faced volatility due to mixed clinical data and given the current valuation and market ...

Dr. Rao previously presented preclinical data supporting the potential of soquelitinib in patients with ALPS. Other trial sites include Children’s Hospital of Philadelphia and Texas Children’s ...

“The data from the Phase 1/1b clinical trial of soquelitinib in patients with T cell lymphoma continues to demonstrate strong indications of anti-tumor activity in a significant number of ...

Corvus Pharmaceuticals (CRVS) announced that additional data from the Company’s Phase 1/1b clinical trial of soquelitinib for the treatment of patients with T cell lymphoma is being presented at ...

Q4 2024 Management View CEO Richard Miller detailed the progress of soquelitinib, emphasizing its potential as a first-in-class oral therapy for immune diseases and cancers. He highlighted the 39% ...

The data from the Phase 1/1b clinical trial of soquelitinib in patients with T cell lymphoma continues to demonstrate strong indications of anti-tumor activity in a significant number of patients,” ...